Literature DB >> 15825414

Pharmacokinetics of tobramycin in patients with stable renal impairment, patients undergoing peritoneal dialysis, and patients on chronic hemodialysis.

G Jaffe, B R Meyers, S Z Hirschman.   

Abstract

The pharmacokinetics of tobramycin were studied in five patients with stable renal impairment, four patients requiring peritoneal dialysis, and four patients on chronic hemodialysis. The half-life of the drug varied with the level of the serum creatinine in the first group of patients, and the average volume of distribution was 15 liters. Only 49% of the administered dose of tobramycin was recovered during 36 h of peritoneal dialysis. The average clearance of tobramycin during hemodialysis was 49.1 ml/min, and 51.5% of the administered dose was recovered during a 6-h dialysis.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 15825414      PMCID: PMC429023          DOI: 10.1128/AAC.5.6.611

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Drug distribution and renal failure.

Authors:  M Gibaldi; D Perrier
Journal:  J Clin Pharmacol New Drugs       Date:  1972 May-Jun

2.  Pharmacologic studies on tobramycin and comparison with gentamicin.

Authors:  B R Meyers; S Z Hirschman
Journal:  J Clin Pharmacol New Drugs       Date:  1972 Aug-Sep

3.  Comparative pharmacokinetics of tobramycin and gentamicin.

Authors:  C Regamey; R C Gordon; W M Kirby
Journal:  Clin Pharmacol Ther       Date:  1973 May-Jun       Impact factor: 6.875

4.  Correlation of serum creatinine concentration and gentamicin half-life.

Authors:  R E Cutler; A M Gyselynck; W P Fleet; A W Forrey
Journal:  JAMA       Date:  1972-02-21       Impact factor: 56.272

5.  Tobramycin: in vitro antibacterial spectrum of a new aminoglycoside.

Authors:  B R Meyers; S Z Hirschman
Journal:  J Clin Pharmacol New Drugs       Date:  1972 Aug-Sep

6.  In vitro studies of tobramycin, an aminoglycoside antibiotic.

Authors:  J Dienstag; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1972-01       Impact factor: 5.191

7.  Pharmacokinetic studies of tobramycin and gentamicin.

Authors:  V K Simon; E U Mösinger; V Malerczy
Journal:  Antimicrob Agents Chemother       Date:  1973-04       Impact factor: 5.191

8.  Pharmacokinetics of the aminoglycoside antibiotic tobramycin in humans.

Authors:  K G Naber; S R Westenfelder; P O Madsen
Journal:  Antimicrob Agents Chemother       Date:  1973-04       Impact factor: 5.191

9.  Tobramycin and gentamicin concentrations in the serum of normal and anephric patients.

Authors:  W R Lockwood; J D Bower
Journal:  Antimicrob Agents Chemother       Date:  1973-01       Impact factor: 5.191

10.  Tobramycin concentrations during peritoneal dialysis.

Authors:  A J Weinstein; A W Karchmer; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1973-10       Impact factor: 5.191

View more
  9 in total

1.  Effect of oral activated charcoal on tobramycin clearance.

Authors:  R L Davis; J R Koup; R A Roon; K E Opheim; A N Smith
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

Review 2.  Clinical pharmacokinetics of aminoglycoside antibiotics.

Authors:  J C Pechere; R Dugal
Journal:  Clin Pharmacokinet       Date:  1979 May-Jun       Impact factor: 6.447

Review 3.  Drug therapy in patients undergoing peritoneal dialysis. Clinical pharmacokinetic considerations.

Authors:  T W Paton; W R Cornish; M A Manuel; B G Hardy
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

4.  The use of tombramycin in the management of severe infections. Clinical and pharmacological data.

Authors:  D Baron; H Drugeon; F Nicolas; A Courtieu
Journal:  Eur J Intensive Care Med       Date:  1976-09

5.  Comparative activity of tobramycin and gentamicin against Pseudomonas, Proteus and Providencia species.

Authors:  I B Ducan; J L Penner
Journal:  Can Med Assoc J       Date:  1975-07-12       Impact factor: 8.262

Review 6.  Tobramycin: a review of its antibacterial and pharmacokinetic properties and therapeutic use.

Authors:  R N Brogden; R M Pinder; P R Sawyer; T M Speight; G S Avery
Journal:  Drugs       Date:  1976       Impact factor: 9.546

7.  Accumulation pharmacokinetics of tobramycin.

Authors:  J J Schentag; G Lasezkay; T J Cumbo; M E Plaut; W J Jusko
Journal:  Antimicrob Agents Chemother       Date:  1978-04       Impact factor: 5.191

8.  Antibiotic blood concentrations in patients successfully treated with tobramycin.

Authors:  M Fiala; S N Chatterjee
Journal:  Postgrad Med J       Date:  1981-09       Impact factor: 2.401

9.  Pharmacokinetics of piperacillin in patients with moderate renal failure and in patients undergoing hemodialysis.

Authors:  J A Giron; B R Meyers; S Z Hirschman; E Srulevitch
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.